{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:08:20Z","timestamp":1761516500537,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.4158\/ep171781.or","type":"journal-article","created":{"date-parts":[[2017,4,27]],"date-time":"2017-04-27T17:08:54Z","timestamp":1493312934000},"page":"787-793","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Bone Turnover in Osteoporotic Women During Long-Term Oral Bisphosphonates Treatment: Implications for Treatment Failure and \u201cDrug Holiday\u201d in the Real World"],"prefix":"10.1016","volume":"23","author":[{"given":"Yair","family":"Liel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ygal","family":"Plakht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Abu","family":"Tailakh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP171781.OR_bb0010","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch Osteoporos"},{"key":"10.4158\/EP171781.OR_bb0015","unstructured":"Osteoporosis Drugs Market. Available at: http:\/\/www.transparencymarketresearch.com\/osteoporosis-drug-market.html. Accessed January 2017."},{"key":"10.4158\/EP171781.OR_bb0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP171781.OR_bb0025","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.4158\/EP.16.6.1016","article-title":"American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations","volume":"16","author":"Watts","year":"2010","journal-title":"Endocr Pract"},{"key":"10.4158\/EP171781.OR_bb0030","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.maturitas.2013.05.013","article-title":"Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013","volume":"75","author":"Compston","year":"2013","journal-title":"Maturitas"},{"key":"10.4158\/EP171781.OR_bb0035","doi-asserted-by":"crossref","first-page":"167","DOI":"10.11005\/jbm.2015.22.4.167","article-title":"Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea","volume":"22","author":"Lee","year":"2015","journal-title":"J Bone Metab"},{"key":"10.4158\/EP171781.OR_bb0040","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4158\/EP171781.OR_bb0045","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s00198-008-0604-4","article-title":"Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday","volume":"19","author":"Curtis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171781.OR_bb0050","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4158\/EP12425.OR","article-title":"Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting","volume":"19","author":"Chiha","year":"2013","journal-title":"Endocr Pract"},{"key":"10.4158\/EP171781.OR_bb0055","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1007\/s00198-015-3447-9","article-title":"Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday","volume":"27","author":"Xu","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171781.OR_bb0060","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171781.OR_bb0065","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cca.2016.06.036","article-title":"Clinical usefulness of bone turnover marker concentrations in osteoporosis","volume":"467","author":"Morris","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.4158\/EP171781.OR_bb0070","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","author":"Diez-Perez","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171781.OR_bb0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.bone.2015.11.021","article-title":"Proportion of osteoporotic women remaining at risk for fracture despite adherence to oral bisphosphonates","volume":"83","author":"Imel","year":"2016","journal-title":"Bone"},{"key":"10.4158\/EP171781.OR_bb0080","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00198-014-2619-3","article-title":"Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis","volume":"25","author":"Cairoli","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171781.OR_bb0085","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00198-016-3720-6","article-title":"Subjects with osteoporosis to remain at high risk for fracture despite benefit of prior bisphosphonate treatment-a Danish case-control study","volume":"28","author":"Hansen","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171781.OR_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171781.OR_bb0095","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/jbmr.2023","article-title":"Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW)","volume":"29","author":"D\u00edez-P\u00e9rez","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP171781.OR_bb0100","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/jbmr.2011","article-title":"Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study","volume":"29","author":"Prieto-Alhambra","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP171781.OR_bb0105","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/jbmr.2595","article-title":"Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study","volume":"31","author":"Hawley","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP171781.OR_bb0110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00198-012-2184-6","article-title":"Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study","volume":"24","author":"Abrahamsen","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171781.OR_bb0115","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/1060028015569594","article-title":"Risk of fracture and the concomitant use of bisphosphonates with osteoporosis-inducing medications","volume":"49","author":"Nyandege","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.4158\/EP171781.OR_bb0120","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"key":"10.4158\/EP171781.OR_bb0125","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1001\/archinternmed.2011.20","article-title":"Proton pump inhibitor use and the antifracture efficacy of alendronate","volume":"171","author":"Abrahamsen","year":"2011","journal-title":"Arch Intern Med"},{"key":"10.4158\/EP171781.OR_bb0130","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00223-014-9842-y","article-title":"A meta-analysis of reference markers of bone turnover for prediction of fracture","volume":"94","author":"Johansson","year":"2014","journal-title":"Calcif Tissue Int"},{"key":"10.4158\/EP171781.OR_bb0135","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/jbmr.342","article-title":"Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP171781.OR_bb0140","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/jbmr.2847","article-title":"Potential usefulness of BMD and bone turnover monitoring of zoledronic acid therapy among women with osteoporosis: secondary analysis of randomised controlled trial data","volume":"31","author":"Bell","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP171781.OR_bb0145","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s00198-016-3561-3","article-title":"The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club","volume":"27","author":"Cavalier","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171781.OR_bb0150","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","article-title":"International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates","volume":"28","author":"Diez-Perez","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171781.OR_bb0155","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/bmj.312.7029.482","article-title":"Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study","volume":"312","author":"van Daele","year":"1996","journal-title":"BMJ"},{"key":"10.4158\/EP171781.OR_bb0160","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study","volume":"15","author":"Garnero","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP171781.OR_bb0165","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00198-009-1108-6","article-title":"Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid","volume":"21","author":"Kaji","year":"2010","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171781.OR_bb0170","first-page":"217","article-title":"Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy","volume":"21","author":"Kitatani","year":"2003","journal-title":"J Bone Miner Metab"},{"key":"10.4158\/EP171781.OR_bb0175","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02672513","article-title":"Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline","volume":"8","author":"Hesley","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171781.OR_bb0180","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s007740050073","article-title":"Urinary pyridinoline and deoxypyridinoline as bone metabolic markers in predicting therapeutic effects of estrogen and alfacalcidol in women with osteoporosis","volume":"17","author":"Zhan","year":"1999","journal-title":"J Bone Miner Metab"},{"key":"10.4158\/EP171781.OR_bb0185","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP171781.OR_bb0190","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jbmr.5650090202","article-title":"Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine","volume":"9","author":"Gertz","year":"1994","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP171781.OR_bb0195","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","article-title":"Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling","volume":"99","author":"Chesnut","year":"1995","journal-title":"Am J Med"},{"key":"10.4158\/EP171781.OR_bb0200","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1359\/jbmr.1998.13.9.1431","article-title":"Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial","volume":"13","author":"Greenspan","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP171781.OR_bb0205","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1359\/jbmr.1999.14.4.602","article-title":"Monitoring alendronate therapy for osteoporosis","volume":"14","author":"Braga de Castro Machado","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP171781.OR_bb0210","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","article-title":"Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate","volume":"41","author":"McClung","year":"2007","journal-title":"Bone"},{"key":"10.4158\/EP171781.OR_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-015-3334-4","article-title":"Treatment of osteoporosis after alendronate or risedronate","volume":"27","author":"Eiken","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP171781.OR_bb0220","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1210\/jc.2016-1801","article-title":"Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates","volume":"101","author":"Miller","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP171781.OR_bb0225","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3109\/00365521.2016.1141317","article-title":"Impaired skeletal health in patients with chronic atrophic gastritis","volume":"51","author":"Aasar\u00f8d","year":"2016","journal-title":"Scand J Gastroenterol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20357918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20357918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:02:53Z","timestamp":1761516173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20357918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1530891X20357918"],"URL":"https:\/\/doi.org\/10.4158\/ep171781.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bone Turnover in Osteoporotic Women During Long-Term Oral Bisphosphonates Treatment: Implications for Treatment Failure and \u201cDrug Holiday\u201d in the Real World","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP171781.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}